Can Polymorphisms Predict Response to Antiarrhythmic Drugs in Atrial Fibrillation???Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the America

With the rationale that the multiple genetic variants associated with AF might indicate variable mechanisms contributing to AF susceptibility, or variable subtypes of AF, Parvez et al. (1) hypothesized that response to AAD therapy might also be genotype dependent. Testing first in a discovery cohort of 478 patients, the authors identified an association between a response to AAD therapy and the rs10033464 SNP, but not with the other SNPs tested. The association with rs10033464 was predominantly, if not exclusively, seen in patients with typical AF as opposed to the patients with lone AF. Using multivariate regression, the tendency to be a nonresponder to AAD therapy for patients carrying a minor allele at rs10033464 persisted after controlling for clinical variables such as age, sex, hypertension, coronary artery disease, heart failure, and diabetes. Interestingly, the investigators further found that the response rate to class I AADs was higher in patients with 1 or more minor alleles at rs10033464. On the other hand, the response rate to class III AADs was higher in patients with only wild-type alleles. In a validation cohort of 178 Caucasian patients with either lone or typical AF from Vanderbilt, the association of rs10033464 with response to ADDs was also significant; subgroup analysis of typical versus lone AF was not performed because of sample size.

Source: http://content.onlinejacc.org/article.aspx?articleID=1206843

mad hatter azerbaijan ryan howard ps i love you ray charles cheney heart transplant weather san diego